Compare Repligen Corporation Common Stock (RGEN) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Upstart Holdings Inc — how do they compare? Repligen Corporation Common Stock trades at $178.85 (market cap $11.31B), while Upstart Holdings Inc trades at $22.4 (market cap $2.21B). The key difference: Repligen Corporation Common Stock is far larger — about 5.1× Upstart Holdings Inc's market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Upstart Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Upstart Holdings Inc for 39 Days on average.
| RGEN | UPST | |
|---|---|---|
Market Cap | $11.31B | $2.21B |
Volume | 1,216,919 | 5,011,542 |
Sector | Health | Financials |
52-Week High | $194.57 | $52.74 |
52-Week Low | $102.87 | $22.74 |
Typical Hold Time | 0 Days | 39 Days |
Enterprise Value | $11.20B | $3.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
UPST trades at $23.83, up 0.34% on the day but remains in a bearish technical trend. The company achieved profitability in 2025 with $1.02B revenue and $53.6M net income, though recent quarters show earnings misses. Analyst consensus is mixed with a $38.13 price target, while technical indicators signal caution with bearish moving averages and neutral oscillators.
The outlook balances AI-driven lending growth potential against execution risks and volatile cash flows. Key opportunities include expanding partnerships and securitization deals, while risks involve credit market sensitivity and rising debt levels. The stock trades at a premium valuation despite recent operational challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
